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A novel enzyme-responsive hydrogel drug delivery system was developed with the potential to treat inﬂammation
locally. Human neutrophil elastase (HNE) is a serine protease secreted by neutrophils which are the ﬁrst cells
recruited to inﬂammatory sites. We exploited this cell-secreted enzyme as a biological cue for controlled release.
HNE sensitive peptide linkers were immobilized within poly(ethylene glycol) hydrogels using photopolymerization
techniques. The kinetics of the enzyme reaction within the gel was tailored by varying the amino acid residues
present in the P1 and P1′ substrate positions (immediately adjacent to cleavage location). A novel FRET-based
hydrogel platform was designed to characterize the accessibility of the substrate within the cross-linked, macroscopic
hydrogel. Lastly, a diffusion-reaction mathematical model with Michaelis-Menten kinetics was developed to
predict the overall release proﬁle and captured the initial 80% of the experimentally observed release. The hydrogel
platform presented shows highly controlled release kinetics with potential applications in cellular responsive drug
delivery.
1. Introduction
A major goal in drug delivery is to control spatially and
temporally the release of therapeutics in vivo. Localized and
sustained drug delivery has the potential to enhance the
therapeutic efﬁcacy of treatment by minimizing systemic drug
concentrations and the need for repeated drug administration.
1
More recently, efforts have been made to fabricate intelligent
drug delivery systems that release therapeutics in response to
physical or biological stimuli, such as temperature,
2,3 pH,
4-6
glucose,
7,8 or enzymes.
9-11 While these systems have provided
great advancements in the area of controlled release, there
remains a need for biomaterials to respond and adapt to cellular
stimuli in the areas of drug delivery and tissue regeneration.
An emerging area of drug delivery focuses on localized,
controlled release in recognition of a cellular response. For
example, human bone morphogenetic protein-2 (BMP-2) has
been entrapped within a 4-arm poly(ethylene glycol) (PEG)
hydrogel cross-linked with matrix metalloproteinases (MMPs)
sensitive peptides. Once implanted at defect sites in rat calvaria,
cell-secreted MMPs were able to degrade the gel and liberate
the encapsulated BMP-2, which promoted cell inﬁltration and
led to remodeling of bony tissue.
12 In another approach, vascular
endothelial growth factor (VEGF) was covalently attached to
ﬁbrin gels through thrombin cleavable substrates for wound
healing applications.
13
A similar approach can be taken to develop enzyme
responsive biomaterials to achieve local drug delivery at sites
of inﬂammation. Inﬂammation has been implicated in wound
healing and many diseases such as diabetes,
14 rheumatoid
arthritis,
15 and cancer.
16 During this biological response,
immune cells inﬁltrate the site of infection/injury and secrete
a variety of biomolecules in a protective attempt to remove
the harmful stimuli. In speciﬁc, neutrophils are the ﬁrst
responding cells to these microenvironments.
17 Upon activa-
tion, neutrophils degranulate and release a variety of enzymes
such as human neutrophil elastase (HNE). An elevated
presence of this enzyme implies a highly speciﬁc biological
event (disease or injury) is occurring, thus making HNE a
desirable triggering molecule for local therapeutic delivery.
18
This serine protease has a speciﬁcity for small, uncharged
amino acids, particularly alanine (A) and valine (V).
19
Synthetic peptides containing the sequence Ala-Ala-Pro-Val
have been studied as HNE speciﬁc substrates
20 for drug
delivery applications.
21 By incorporating a similar elastase
sensitive peptide into a biomaterial, an increased local
concentration of HNE at sites of degranulation can be used
as a cellular cue to release an anti-inﬂammatory therapeu-
tic.
In this contribution, we present and characterize a drug
delivery platform with the potential to achieve HNE-triggered,
controlled, and localized drug release from PEG hydrogels.
Speciﬁcally, HNE-sensitive linkers were photopolymerized into
PEG diacrylate (PEGDA) hydrogels as pendent groups as seen
in Scheme 1. Upon the onset of an inﬂammatory response, HNE
diffuses into the PEG hydrogels and cleaves its respective
substrate liberating a therapeutic to the local environment.
Research has shown that the amino acid positions directly
adjacent to enzyme cleavage location (P1 and P1′) are important
for varying proteolytic reaction rates.
22,23 This work examines
the effect of point variations within the elastase substrate at
speciﬁed locations on the cleavage kinetics and exploits these
differences to obtain varying release proﬁles from the hydrogel.
In addition, a Fo ¨rster resonance energy transfer (FRET)-based
hydrogel was developed to characterize the accessibility of the
substrate to the enzyme within a cross-linked polymer network.
Lastly, a diffusion-reaction model, taking into account both
molecular diffusion and Michaelis-Menten kinetics, was de-
veloped to better understand the mechanisms dominating release
from the HNE-responsive hydrogels.
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Materials. Poly(ethylene glycol) (PEG, Mn ∼ 10000) was obtained
from Aldrich (St. Louis, MO). Monoacrylate-PEG-N-hydroxysuccin-
imide (APEG-NHS, Mn ∼ 3400) was purchased from Laysan Bio, Inc.
(Arab, AL). Fmoc-protected amino acids in their L-conﬁguration as
well as O-benzotriazole-N,N,N′,N′-tetramethyl-uronium-hexaﬂuoro-
phosphate (HBTU), 1-hydroxybenzotriazole hydrate (HOBt), and 2-(1H-
7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uronium hexaﬂuorophos-
phate methanaminium (HATU) used for amino acid activation were
obtained from Anaspec (San Jose, CA). MBHA Rink Amide resin was
purchased from Novabiochem (La Jolla, CA). 5(6)-Carboxyrhodamine
(ROX) and QXL 610 acid (QXL) were obtained from Anaspec.
Fluorescamine was provided by Sigma-Aldrich (St. Louis, MO). Human
neutrophil elastase (HNE) was supplied as a lyophilized powder from
Innovative Research (Novi, MI).
Poly(ethylene glycol) Diacrylate (PEGDA10k) Synthesis. Linear
PEGDA10k was synthesized similar to reported literature
24 by reacting
PEG (Mn ∼ 10000) with a 8 molar excess of acryloyl chloride in the
presence of triethyleamine (TEA). The reaction was allowed to proceed
overnight at room temperature protected from light. The acrylated PEG
was ﬁltered through a bed of alumina to remove the TEA-HCl
complex. Toluene was then removed from the reaction mixture under
rotary evaporation. To obtain pure PEGDA10k, the crude product was
dissolved in methylene chloride and precipitated in cold diethyl ether.
The puriﬁed product was then ﬁltered and dried in vacuo at room
temperature. The degree of acrylation was conﬁrmed to be >90% by
1H NMR (Supporting Information).
Peptide Synthesis. Peptide sequences (Table 1) were synthesized
(Applied Biosystem 433A Peptide Synthesizer) using solid phase Fmoc
chemistry on a MHBA Rink Amide Resin (∼0.7 mmol/g resin
substitution). Peptides were cleaved from their solid support using
triﬂuoroacetic acid (TFA)/triisopropylsilane (TIS)/water (95/2.5/2.5 v/v)
and allowed to react at room temperature for 2 h. The reaction was
ﬁltered and the ﬁltrate precipitated and washed (3×) in chilled diethyl
ether. Peptides were puriﬁed by semipreparative reversed phase HPLC
(Waters Delta Prep 4000) using a 70 min linear (5-95%) gradient of
acetonitrile in 0.1% triﬂuoroacetic acid. Peptide purity was conﬁrmed
by analytical reversed phase HPLC C18 column and matrix-assisted
laser desorption ionization time-of-ﬂight mass spectrometry (Applied
Biosystem DE Voyager).
Kinetic Analysis of Substrate Degradation. Degradation kinetic
parameters were determined using a ﬂuorescamine ﬂuorometric assay.
25
To measure accurately the concentrations of cleaved peptide fragments,
the N-terminal amines of the HNE substrate peptides were capped with
Scheme 1. Photopolymerization of PEGDA with an Acrylated HNE-Sensitive Substrate
Table 1. HNE-Sensitive Peptides Synthesized Showing Point Variations in the P1 and P1′ Positions
a
a Arrow indicates cleavage location. Unless otherwise noted, the default amino acid for the P1 position was Val and Gly for the P1′ position. Non-
native amino acid abbreviations represent Abu ) aminobutyric acid, Nva ) norvaline, and Nle ) norleucine.
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HEPES + 150 mM NaCl pH 7.4) at varying concentrations and HNE
was added (30nM). The reaction mixture was sampled at 5-min intervals
and allowed to further react with ﬂuorescamine (2 mg/mL in acetoni-
trile) for determining the concentrations of cleaved peptides (ﬂuores-
cence was detected at λexcitation ) 380 nm, λemission ) 460 nm, Perkin-
Elmer Wallac Victor
2 1420 Multilabel Counter). Cleavage product
concentration was determined using presynthesized peptide fragments
as an external calibration. Michaelis-Menten enzyme kinetic analysis
was performed and speciﬁcity constants (kcat/Km) were determined using
nonlinear regression analysis (Graphpad Prism 5). Substrate cleavage
site was conﬁrmed by RP-HPLC analysis. The peptide fragments were
isolated and analyzed with electrospray ionization mass spectrometry
to determine the amino acid composition within the fragment.
Synthesis of HNE-Cleavable FRET Substrate. The peptide
K(ROX)AAPVVRGGGK(QXL) was synthesized as follows (where
arrow indicates cleavage location). Fmoc-Lys(Mtt)-OH was allowed
to couple to the resin (HATU/N,N′-diisopropylethylamine (DIPEA))
for 2 h. The resin was then treated with 1.8% TFA in dichloromethane
for 30 s, repeated nine times
26 to selectively remove the Mtt protecting
group on Lys. A ninhydrin test was performed to conﬁrm the complete
removal of the Mtt protecting group. QXL was then reacted to the
deprotected  -amino group (HATU/DIPEA) on Lys for 2 h. The resin
was then thoroughly washed with DMF and placed on the ABI 433A
Peptide Synthesizer for automated couplings. After peptide synthesis,
Fmoc-K(Mtt)AAPVRGGGK(QXL)-resin was removed from the instru-
ment and the Mtt group selectively deprotected as described above.
ROX was reacted to the N-terminal Lys  -amino group using HATU/
DIPEA coupling chemistry. The terminal Fmoc group was manually
removed (20% piperidine in DMF). Finally, the product was cleaved
from the resin and puriﬁed as described above. The product was
conﬁrmed using MALDI-MS.
Visualization of HNE Activity in PEG Hydrogel. Acrylate-PEG-
NHS (5 equiv) was reacted to the N-terminal amine of the FRET
substrate in 0.1 M sodium phosphate buffer pH 8.0 for 4 h protec-
ted from light. The desired product (Acryl-PEG-K(ROX)-
AAPVVRGGGK(QXL)) was isolated using RP-HPLC and resulted in
a lyophilized powder. Upon HNE dictated cleavage, the QXL quencher
is able to diffuse away, leaving ﬂuorescent ROX that provides spatial
evidence of HNE activity within our gels. FRET hydrogels were formed
from a precursor solution of 10 wt % PEGDA10k in phosphate buffer
(PBS), 0.025 wt % of the photoinitiator 2-hydroxy-1-[4-(hydroxyethox-
y)phenyl]-2-methyl-1-propanone (I-2959, Ciba-Geigy), and 4 mM acryl-
PEG-K(ROX)AAPVRGGGK(QXL), exposed to 365 nm ultraviolet
light for 10 min. Gels were treated with 1 µM HNE and 3-dimensional
ﬂuorescence image stacks, spanning the thickness of the hydrogel, were
captured at predetermined time points using confocal microscopy (Zeiss
Pascal LSM 5). ROX was excited using a 543 nm helium-neon laser
and ﬂuorescence was collected using a 560 nm long pass ﬁlter.
HNE Dictated Release From PEG Hydrogel. Two HNE substrates
analyzed using the solution phase assay were further studied in an
immobilized hydrogel system. Peptides AAPVVRGMG and AAP(Nva)
VGGMG were acrylated with conjugation to APEG-NHS and puriﬁed
as described previously. Methionine residues were substituted for
cysteine residues, as used previously, to prevent thiol-acrylate reaction
during photopolymerization. Hydrogels were formed via free radical
photopolymerization from the macromer solution containing 10 wt %
PEGDA10k, 5 mM APEG-peptide, and 0.025 wt % I-2959 under
standard conditions described previously. Cylindrical disks (diameter
) 5 mm, thickness ) 600 µm) were formed using a biopsy punch.
Roughly 85% of the APEG-peptide was incorporated during the
photopolymerization, which is comparable to previous literature using
similar reaction conditions.
27 This was determined by swelling the gels
in buffer for 24 h and exposing the supernatant to HNE (1 µM). The
reaction was allowed to proceed for2ht oensure complete substrate
cleavage. Fluorescamine was added and the amount of peptide in the
buffer solution was determined using an external calibration with
the peptide fragment. Gels (n ) 3) were then transferred to 100 µLo f
fresh HEPES buffer and 1 µM HNE was added. At predetermined time
points, samples were analyzed for peptide fragment release using
ﬂuorescamine. Buffer and enzyme was replenished at each time point.
3. Results and Discussion
3.1. Solution Phase Enzyme Kinetic Analysis of HNE
Substrates. To tailor drug delivery in enzyme responsive
materials, it is important to characterize the kinetic rate at which
the enzyme is breaking down its respective substrate. HNE
substrates were synthesized with point variations in the P1 and
P1′ amino acid positions with the goal of manipulating the
reaction kinetics. Rational design was used to vary residues
within these locations. Previous literature reports that HNE
speciﬁcity for its substrate depends greatly on S′-P′ interac-
tions.
28 Therefore, we examined a charged amino acid (Arg), a
neutral, hydrophilic residue (Gln), a hydrophobic, aliphatic
amino acid (Leu), and a hydrophobic, aromatic residue (Phe)
in the P1′ location (Table 1). Figure 1a shows that hydrophobic
Figure 1. Solution phase hydrolysis of peptides by HNE. The values of kcat and Km for point variations in the P1′ (a) and P1 (b) substrate
positions. Kinetic constants for the control substrate Ac-YAAPVVGGCG were Km ) 160 ( 20 µM and kcat ) 2.68 ( 0.08 s-1. Arrow indicates
cleavage location. (c) Representative Michaelis-Menten plot. (d) Representative HPLC chromatogram showing pure peptide (dashed line) and
peptide and HNE reaction mixture (solid lines).
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(∼Km) similar to previous reports.
28 Km values ranged from 150
µM (Arg in P1′ position) to 50 µM (Phe in P1′ position). An
increase in substrate hydrophobicity led to a decrease in Km
values indicating enhanced protein-peptide afﬁnity. Incorpora-
tion of an Arg residue enhanced the catalytic efﬁciency similar
to studies by Korkmaz et al.
29 An ∼2.5-fold difference was seen
in kcat values ranging from 3.1 to 1.3 s-1 for Arg and Phe P1′
containing peptides, respectively. Electrostatic interactions could
contribute to this result based on the surface charge distribution
on HNE, as HNE exhibits a slightly negative surface charge in
close proximity to the catalytic site.
29 In addition, a scrambled
peptide exhibited resistance to HNE cleavage showing speciﬁcity
of the other substrates.
In further attempts to tailor the kinetic rate of HNE-mediated
substrate degradation, we studied the incorporation of non-
natural amino acids in the P1 position (Table 1). HNE is known
to prefer short, aliphatic amino acids in the P1 site.
30,31 The S1
pocket of HNE is shallow compared to its serine protease
counterparts due to the presence of Val-190 and Val-216
residues.
32 Therefore, we investigated non-native residues whose
side chains differ by varying numbers of methylene groups.
Figure 1b indicates there is a preferred size of the P1 side chain
length (Abu with ethyl group) for effective HNE substrate
degradation. HNE degraded substrates containing a short P1
amino acid side chain (Ala) and longer P1 residue side chains
(Nle) at a rate constant of 0.18 and 0.07 s-1, respectively. A
maximum kcat constant (1.1 s-1) for P1 amino acid variations
was found with an Abu (ethyl side chain) containing peptide.
The Michaelis constant remained similar (240-290 µM) for
the P1 varied substrates indicating comparable protein-peptide
afﬁnity. These results demonstrate that the point variations on
HNE substrate peptides affect the catalytic activity of HNE.
Figure 1c contains a representative Michaelis-Menten plot
(substrate: Ac-YAAPVRGCG) illustrating the enzyme kinetics
of HNE dictated substrate cleavage. Further, HPLC was used
to separate the peptide fragments and nondegraded peptide
within an HNE-peptide containing reaction mixture. Nonde-
graded peptide and two peptide fragment peaks are observed
in Figure 1d corresponding to Ac-YAAPVRGCG and Ac-
YAAPV/RGCG, respectively (MALDI spectra can be found in
Supporting Information).
In conclusion, it was possible to alter the rates of HNE-
dictated cleavage by simply varying a single amino acid residue
in speciﬁc locations along the substrate sequence. The results
presented herein provide the foundation for achieving tailorable
HNE-responsive drug delivery from PEG hydrogels.
3.2. Visualizing HNE Activity in a PEG Hydrogel
Using FRET. When designing enzyme responsive delivery
platforms, it is critical to understand the accessibility of the
substrate to the enzyme.
33 PEGDA photopolymerized hydrogels
are highly cross-linked, three-dimensional polymeric networks.
This structure impedes (and at some molecular weight cut off
denies) the diffusion of proteins through the hydrogel network.
Other than pathological reasons, HNE was chosen as a triggering
molecule due its relative small size (∼29.5 kDa) and ability to
penetrate the hydrogel.
34 By incorporating a FRET based HNE
substrate within the hydrogel, HNE spatial activity could be
visualized using confocal microscopy. We developed a FRET
hydrogel system where a ﬂuorophore/quencher HNE substrate
(K(ROX)AAPVVRGGGK(QXL)) was photopolymerized within
a PEG hydrogel. Upon HNE dictated cleavage, the QXL
quencher was able to diffuse out of the gel allowing for the
detection of the ROX ﬂuorophore. Figure 2 shows the enzyme
cleavage front as a function of space and time. Figure 2a shows
a uniform ﬂuorescence proﬁle over the thickness of the hydrogel.
Over time, an increase in normalized ﬂuorescence was initially
observed at the gel edges and propagated inward toward the
center. At t ) 10 min, increased uniform ﬂuorescence (∼2.5
times the initial value) was observed through the z-direction of
the gel. Our results indicate that HNE is able to access the center
of the hydrogel within a reasonable time scale (minutes), but
both mass transfer and kinetics are important in dictating the
overall release proﬁle.
3.3. Modeling Enzymatic Cleavage and Release from
PEG Hydrogel. To predict release proﬁles from this system, a
reaction-diffusion model was developed, based on similar
approaches in the literature.
35,36 Brieﬂy, substrate cleavage was
assumed to be governed by Michaelis-Menten kinetics (Figure
1) with a spatially heterogeneous HNE concentration dictated
by HNE’s diffusion into the gel as well as its measured half-
life. The cleaved product then diffused out of the hydrogel and
the product residing in the supernatant at each time point was
measured.
The diffusion of HNE was modeled by unidirectional, Fickian
diffusion through the vertical axis of the hydrogel such that
∂[HNE](z,t)
∂t
) DE
∂
2[HNE](z,t)
∂z
2 (1)
where DE is the diffusion coefﬁcient of the enzyme in the gel
and [HNE] is the concentration of enzyme at a given point in
space and time. The diffusion coefﬁcient of HNE (DE ) 5 ×
10-7 cm2 s-1) was estimated from studies with a similar size
Figure 2. Spatial HNE activity progression at (a) 0, (b) 1, (c) 3, (d) 5, and (e) 10 min throughout the thickness of a hydrogel. Scale bars ) 200
µm. Graphs depict quantitative ﬂuorescence analysis as a function of a representative hydrogel thickness.
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similar gel chemistry.
34 At the surface (x ) 0) of the hydrogel,
a boundary condition was set as [HNE] ) [HNE]0, where
[HNE]0 is the concentration of enzyme in solution. At the center
of the gel, the symmetry boundary condition was employed.
Solving eq 1 and the corresponding boundary conditions leads
to the solution
[HNE](z,t) ) [HNE]0(1 - 4
π∑
n)0
∞
(-1)n
2n + 1
×
exp [-DE(2n + 1)2 π
2t
4h
2]cos [
(2n + 1)πz
2h ]) (2)
where h is the half-thickness of the gel (h ) 300 µm). When
the spatial proﬁle of enzyme concentration from eq 2 was used
and assuming that the cleavage of substrate follows Michaelis-
Menten kinetics, the amount of substrate cleaved and product
formed at each point in the gel is predicted by the following
kinetic equations
-∂[S](z,t)
∂t
) ∂[P](z,t)
∂t
) [HNE](z,t)kcat
[S]
Km + [S]
(3)
where [S] is the concentration of substrate, kcat is the kinetic
constant for formation of product for the given HNE-substrate
pair, as measured in solution, Km is the Michaelis constant for
the given HNE-substrate pair as measured in solution, and [P]
is the concentration of cleaved product. The diffusion of the
cleaved product is also modeled by unidirectional, Fickian
diffusion through the vertical axis of the gel such that
∂[P](z,t)
∂t
) DP
∂
2[P](z,t)
∂z
2 (4)
where DP is the diffusion coefﬁcient of the cleaved product in
the gel. The product diffusion coefﬁcient in dilute solutions was
ﬁrst approximated using the Stokes-Einstein equation (eq 5).
D0 )
kBT
6πηrs
(5)
When a correlation developed by Lustig et al.
37 was used,
DP in a cross-linked hydrogel was calculated to be 4.0 × 10-6
cm2/s. This relationship can be used to approximate the diffusion
of various molecules, such as small molecules or globular
proteins, because it takes into account the hydrodynamic radius
of the solute, the mesh size of the cross-linked network, and
the volume degree of swelling for the gel. Product diffusion
was modeled numerically using a second-order, centered dif-
ference approximation of the second-derivate.
Figure 3 shows the experimentally measured and predicted
release proﬁles using two HNE substrates (AAPVRGMG,
AAP(Nva)GGMG) and varying concentrations of HNE. The two
substrates examined were chosen based on the varying catalytic
rates determined previously. Figure 3a shows varying release
rates as a function of HNE concentration with the incorporation
of substrate AAPVRGMG. Exogenously adding 1 µM HNE
resulted in complete peptide release about 1 h, whereas 100
nM HNE dictated release occurred over 6 h. Figure 3b illustrates
peptide release proﬁles from incorporated substrates with
varying enzyme kinetic rates. For all systems where the reaction
rate was increased (increased [HNE] or kcat) there was an
increasing linear release response at t g 0. However, when the
rate of reaction was decreased (decreased [HNE] or kcat), the
data depicts an initial delay in release, which is most likely
attributed to diffusion limitations. The model agrees with the
experimental values up to 80% release. At this point, the model
and the experimental results deviate, which is likely due to the
complexity of the system at later time points. As substrate is
being converted to product, free carboxylic acids are present
forming a more polyelectrolyte hydrogel. Upon HNE cleavage,
the peptide fragments diffusing out of the gel (product) are
cationic. Electrostatic attraction between the gel and the product
could potentially decrease the diffusion rate out the gel.
38 This
phenomenon would result in the mathematical model over
predicting the rate of release as observed.
These results focus on the ability to tune release from the
developed platform. To further enhance the value of the system,
anti-inﬂammatory therapeutics can be covalently attached to the
released peptide fragment through various bioconjugation
techniques. Speciﬁcally, small molecule drugs such as lisofyl-
line,
39 ketoprofen,
40 and D-penicillamine
41 are of interest due
to their function and ability to incorporate onto the HNE
substrate.
4. Conclusion
An enzyme responsive PEG hydrogel platform was developed
to achieve HNE triggered release to the local environment. The
rate of enzyme reaction (substrate degradation) can be tailored
by incorporation and/or substitution of different amino acids in
speciﬁc locations of the substrate. A novel FRET-based hydrogel
platform was fabricated to image enzyme activity throughout
the thickness of the macroscopic gel. The release from the
hydrogel can be modeled using a diffusion-reaction model with
molecular diffusion and Michaelis-Menten kinetics. This work
fully characterized the drug delivery platform and exhibited the
ability to achieve local, controlled release in the presence of
HNE. In addition, this system could be further expanded to target
other cell-secreted enzymes to target different stages of inﬂam-
mation. Further studies involving conjugation of an active
therapeutic to the substrate are necessary to validate the system.
Figure 3. Peptide release proﬁles as a function of time from hydrogel
in the presence of (a) varying HNE concentrations and (b) varying
HNE substrates. Solid lines indicate diffusion-reaction model results.
Error bars indicate standard deviation (n ) 3).
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